Curis, Inc.

NasdaqCM:CRIS Stock Report

Market Cap: US$16.0m

Curis Management

Management criteria checks 2/4

Curis' CEO is Jim Dentzer, appointed in Sep 2018, has a tenure of 6.67 years. total yearly compensation is $1.97M, comprised of 33.1% salary and 66.9% bonuses, including company stock and options. directly owns 0.099% of the company’s shares, worth $15.86K. The average tenure of the management team and the board of directors is 4.7 years and 10.8 years respectively.

Key information

Jim Dentzer

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage33.1%
CEO tenure6.7yrs
CEO ownership0.1%
Management average tenure4.7yrs
Board average tenure10.8yrs

Recent management updates

Recent updates

author-image

FDA And EMA Will Accelerate Emavusertib Clinical Trials

Apr 14 Feedback from regulatory bodies can expedite market entry for emavusertib, potentially accelerating revenue and competitive advantage in the CNS lymphoma space.

Analysts Just Published A Bright New Outlook For Curis, Inc.'s (NASDAQ:CRIS)

Apr 02
Analysts Just Published A Bright New Outlook For Curis, Inc.'s (NASDAQ:CRIS)

Investors Don't See Light At End Of Curis, Inc.'s (NASDAQ:CRIS) Tunnel And Push Stock Down 30%

Apr 01
Investors Don't See Light At End Of Curis, Inc.'s (NASDAQ:CRIS) Tunnel And Push Stock Down 30%

Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues

Dec 29
Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues

Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues

Nov 14
Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues

Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%

Aug 07
Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%

Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet

Aug 05
Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 03
Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Dec 26
Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate

Nov 03
We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate

We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

Aug 05
We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Apr 19
Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Jan 02
Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Sep 16
Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Aug 18

Curis: Asymmetric Risk And Reward

Jul 17

CEO Compensation Analysis

How has Jim Dentzer's remuneration changed compared to Curis's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$42m

Dec 31 2024US$2mUS$653k

-US$43m

Sep 30 2024n/an/a

-US$45m

Jun 30 2024n/an/a

-US$48m

Mar 31 2024n/an/a

-US$48m

Dec 31 2023US$2mUS$634k

-US$47m

Sep 30 2023n/an/a

-US$47m

Jun 30 2023n/an/a

-US$48m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$3mUS$615k

-US$57m

Sep 30 2022n/an/a

-US$59m

Jun 30 2022n/an/a

-US$57m

Mar 31 2022n/an/a

-US$52m

Dec 31 2021US$3mUS$590k

-US$45m

Sep 30 2021n/an/a

-US$39m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$30m

Dec 31 2020US$2mUS$545k

-US$30m

Sep 30 2020n/an/a

-US$31m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$32m

Dec 31 2019US$2mUS$510k

-US$32m

Sep 30 2019n/an/a

-US$29m

Jun 30 2019n/an/a

-US$30m

Mar 31 2019n/an/a

-US$32m

Dec 31 2018US$2mUS$479k

-US$33m

Compensation vs Market: Jim's total compensation ($USD1.97M) is above average for companies of similar size in the US market ($USD679.45K).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.

CEO

Jim Dentzer (57 yo)

6.7yrs

Tenure

US$1,973,386

Compensation

Mr. James E. Dentzer, also known as Jim, serves as Independent Director of Imunon, Inc. since September 2022. He serves as President, Chief Executive Officer & Director since September 24, 2018 and Secreta...

Leadership Team

NamePositionTenureCompensationOwnership
James Dentzer
President6.7yrsUS$1.97m0.099%
$ 15.9k
Diantha Duvall
CFO and Principal Financial & Accounting Officer2.8yrsUS$1.07m0.058%
$ 9.3k
Jonathan Zung
Chief Development Officer2yrsUS$1.10m0%
$ 0
Mark Noel
Vice President of Technology Management & Intellectual Property16.7yrsUS$413.39kno data
Robert Martell
Chief Scientific Officerno dataUS$1.17mno data
Nancy Soohoo
VP & General Counselno datano datano data
Rachel Blasbalg
Senior Director of Human Resourcesno datano datano data
Ahmed Hamdy
Chief Medical Officerno datano datano data

4.7yrs

Average Tenure

58.5yo

Average Age

Experienced Management: CRIS's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James Dentzer
President6.7yrsUS$1.97m0.099%
$ 15.9k
Martyn Greenacre
Independent Chairman of the Board25.3yrsUS$144.22k0.015%
$ 2.5k
Marc Rubin
Independent Director14.9yrsUS$109.22k0.017%
$ 2.7k
Kenneth Kaitin
Independent Director21.5yrsUS$111.72k0.017%
$ 2.7k
Alexander Perl
Member of AML & MDS Advisory Boardno datano datano data
John Hohneker
Independent Director3.4yrsUS$91.72k0%
$ 0
Anne Borgman-Hagey
Independent Director2.6yrsUS$89.22k0%
$ 0
David Sallman
Member of AML & MDS Advisory Boardno datano datano data
Amit Verma
Member of AML & MDS Advisory Boardno datano datano data
Guillermo Garcia-Manero
Member of AML & MDS Advisory Boardno datano datano data
Eric Winer
Member of AML & MDS Advisory Boardno datano datano data
Christian Grommes
Member of Lymphoma Advisory Boardno datano datano data

10.8yrs

Average Tenure

66.5yo

Average Age

Experienced Board: CRIS's board of directors are seasoned and experienced ( 10.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 02:19
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Curis, Inc. is covered by 24 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
James BirchenoughBMO Capital Markets Equity Research
Brian SkorneyBrean Capital